MetaOptics Ltd (Catalist: 9MT) (“MetaOptics” or the “Company”, and together with its subsidiaries, the “Group”) recently ...

Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 ...

Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...

SINGAPORE, March 20, 2026 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group") recently announced a series of strategic ...

Donald Trump's war against Iran is part of a terrifying new era of American imperialism, one in which the military budget never stops growing.

The automotive EBIT margin came in at 5.3%. Excluding the EUR 1.3 billion depreciation resulting from the PPA of BMW Brilliance Automotive, the EBIT margin reached 6.4% for the year. And that still ...

For both the fourth quarter and full year 2025, the increases in R&D expenses were primarily due to higher clinical trial and ...

GPGI, Inc. (NYSE:GPGI) Q4 2025 Earnings Call Transcript March 12, 2026 GPGI, Inc. misses on earnings expectations. Reported EPS is $0.23 EPS, expectations were $0.2336. Operator: Good day, and thank ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...

Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.